MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
INKT•Initial Agent-797 patient update
Aug. 6 (Reuters) - MiNK Therapeutics Inc (INKT.O):
- MiNK Therapeutics said no major serious adverse events were attributed to Agent-797 in the first patients.
- The first Agent-797 patients were alive and afebrile at day 28 with improved oxygenation.
- Enrollment continues in Lviv with U.S. sites opening; additional data is expected early 2027.
